Human pharmaceutical business

Eli Lilly’s (LLY) human pharmaceutical business reported revenues of $5.0 billion in 2Q17, an 11.0% rise compared to $4.5 billion in 2Q16. Eli Lilly’s new products include Basaglar, Lartruvo, Cyramza, Olumiant, Jardiance, Taltz, and Trulicity.

Quarterly Performance of Eli Lilly’s New Products

The above chart shows revenues for new products over the last few quarters. Let’s look next at the performances of each of the products.


Basaglar, an insulin glargine injection to control blood sugar levels in people with diabetes, reported revenues of $86.6 million in 2Q17, including US sales of $60.0 million and international sales of $27.0 million. The drug was launched in US markets in 4Q16.


Lartruvo, a drug for the treatment of people with advanced soft tissue sarcoma, reported revenues of $47.4 million in 2Q17. The drug was launched in the United States as well as European markets in 4Q16.


Cyramza, an oncology drug for the treatment of metastatic non-small cell lung cancer, metastatic colorectal cancer, and advanced gastric cancer, reported a rise of 27.0% in 2Q17 sales to $186.3 million compared to 2Q16. The rise was driven by strong sales in European and Japanese markets.


Jardiance, a drug used to lower blood sugar levels in people with type 2 diabetes, is part of the diabetes alliance between Eli Lilly and Boehringer Ingelheim. Jardiance reported sales of $103.2 million in 2Q17, driven by increased demand across the US and international markets.


Taltz, a drug for the treatment of plaque psoriasis, reported revenues of $138.7 million in 2Q17. The drug was launched in the US and European markets in 2Q16. US markets contribute a major portion of Taltz sales, reporting sales of $124.0 million in 2Q17.


Trulicity, a drug for improving blood sugar levels in people with type 2 diabetes, reported more than 100% growth in its 2Q17 sales to $480.2 million compared to $201.3 million in 2Q16. Growth was driven by increased demand in US markets.

The Vanguard Healthcare ETF (VHT) holds 2.3% of its total assets in Eli Lilly (LLY). VHT also holds 2.7% in Bristol-Myers Squibb (BMY), 3.1% in AbbVie (ABBV), and 2.4% in Abbott Laboratories (ABT).

Latest articles

This year, Pfizer (PFE) stock has fallen 0.34% and Bristol-Myers Squibb (BMY) stock has fallen 6.48%. Both companies are focused on strengthening their position in the high-growth oncology and immunology markets. Let's take a closer look at each.

Walt Disney’s (DIS) latest movie, Toy Story 4, has reportedly broken records in the opening weekend with $118 million in sales. However, the opening weekend collection was behind analysts’ expectations of at least $150 million in the first weekend.

24 Jun

Will Home Depot’s Upward Momentum to Continue?

WRITTEN BY Rajiv Nanjapla

As of June 21, Home Depot (HD) was trading at $209.39, which implies a rise of 9.7% since the announcement of its first-quarter earnings on May 21. Also, the company was trading at a premium of 32.4% from its 52-week low of $158.09 and a discount of 2.8% from its 52-week high of $215.43.

On June 21, Aurora Cannabis (ACB) made an announcement that indicated that it will move towards higher margin vape products. In addition, the company also believes concentrates and edibles will command higher margins. In anticipation of this development, the company announced the expansion of its facility to capitalize on growth related to these segments.

Shares of Mondelēz International (MDLZ) are scaling new heights thanks to its stellar gains so far this year. Mondelēz stock is up 38.0% on a YTD (year-to-date) basis, and it closed at $55.25—just a shade lower than its 52-week high of $55.71—on June 21.

24 Jun

How Long Will Facebook's Libra Fuel Bitcoin Rally?

WRITTEN BY Mayur Sontakke, CFA, FRM

Ever since the news about Facebook’s (FB) cryptocurrency project broke, Bitcoin has rallied on the hope that Facebook’s entry in the space will help make cryptocurrencies mainstream. Facebook’s cryptocurrency will be called Libra and will be governed by an association with 28 founding members across industries.